VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
MDWD
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
MDWDMediWound Ltd.
$14.25$183M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. MDWD
  4. Financial Ratios

MediWound Ltd. (MDWD) Financial Ratios

Latest Ratios: P/E Ratio -9.1x · EV/EBITDA N/A · ROE -63.9%. (2012–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

MDWD Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$183M$210M$177M$92M$67M$64M$101M$84M$110M$104M$100M
Enterprise Value$186M$213M$175M$86M$34M$55M$85M$79M$103M$68M$71M
P/E Ratio →-9.10——————17.22———
P/S Ratio15.4312.388.774.912.542.714.632.6532.3641.6164.24
P/B Ratio3.724.815.692.906.16—13.845.5512.2710.8012.88
P/FCF———————11.24———
P/OCF———————10.17———

P/E links to full P/E history page with 30-year chart

MDWD EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—12.588.664.611.292.303.912.4930.3927.1645.72
EV / EBITDA———————14.01———
EV / EBIT———————26.42———
EV / FCF———————10.54———

MDWD Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin19.2%19.2%13.0%19.1%49.7%36.9%34.7%62.7%38.6%36.8%-38.5%
Operating Margin-149.1%-149.1%-95.8%-83.0%-28.9%-47.2%-40.6%14.1%-116.4%-548.4%-1293.6%
Net Profit Margin-140.8%-140.8%-149.5%-35.9%-74.0%-57.0%-42.3%15.6%-31.1%-887.4%-1212.1%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE-63.9%-63.9%-96.3%-31.6%-619.0%-1007.5%-82.0%41.1%-11.4%-254.7%-120.9%
ROA-29.9%-29.9%-43.2%-11.5%-56.2%-53.3%-25.7%13.1%-2.7%-55.4%-42.8%
ROIC-49.9%-49.9%-52.9%-589.5%——-844.6%55.3%———
ROCE-47.0%-47.0%-37.8%-33.1%-32.6%-70.5%-33.3%14.8%-11.5%-39.6%-51.9%

MDWD Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity0.190.190.220.200.08—0.240.13———
Debt / EBITDA———————0.36———
Net Debt / Equity—0.08-0.07-0.17-3.03—-2.15-0.35-0.75-3.75-3.72
Net Debt / EBITDA———————-0.93———
Debt / FCF———————-0.70———
Interest Coverage-35.19-35.19-52.43-18.22-120.50-75.57-42.2214.45———

MDWD Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio2.332.331.974.593.801.393.173.436.687.646.25
Quick Ratio2.172.171.864.333.641.283.003.286.347.306.09
Cash Ratio2.072.071.633.842.811.032.592.824.836.645.58
Asset Turnover—0.200.280.280.531.200.700.780.100.060.04
Inventory Turnover3.353.356.535.316.7912.4910.307.351.240.842.56
Days Sales Outstanding—51.05105.6386.32133.5634.8247.6349.77780.01502.46641.68

MDWD Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield———————————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield———————5.8%———
FCF Yield———————8.9%———
Buyback Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Total Shareholder Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Shares Outstanding—$11M$10M$9M$5M$4M$4M$4M$4M$3M$3M

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetMixed
Cash FlowBurning
Top Statement Risk

Persistent operating losses and cash burn

Premium Sales Multiple Against Collapsing Earnings

Based on current figures, MDWD trades at a P/S of 10.79 and P/B of 3.72 despite negative trailing P/E of -6.79, meaning the market is pricing a recovery the reported ratios do not yet show.

A price-to-sales multiple near 10.8 is high for a company whose quarterly revenue fell sharply year over year, suggesting investors are capitalizing a future inflection rather than current economics. The P/B of 3.72 similarly implies the market values the asset base well above book, which warrants scrutiny given persistent negative returns on equity. Without forward multiples or EV/EBITDA available, the valuation rests heavily on sales and book value, and investors should monitor whether revenue stabilization materializes before the premium can be justified.

Gross Margin Thin and Operating Losses Deep

Gross margin ranged from 8.8% to 23.5% over ten quarters while operating margin stayed below -75% in every period, indicating a cost base that far exceeds gross profit generation.

The recent 10.9% gross margin sits near the bottom of its ten-quarter band, which limits the company's capacity to absorb operating expenses even in favorable periods. Operating margins of roughly -3.1% in the latest quarter are a marked improvement from the -120% and -132% readings in 2025, but this improvement coincides with a revenue base that has shrunk, so the ratio may partly reflect a smaller denominator of costs rather than structural efficiency gains. Earning power should be judged on gross margin trajectory and cost discipline, not on the narrowing operating ratio alone.

Persistent Negative Returns on Invested Capital

ROIC has remained negative across all ten quarters, ranging from -13.9% to -41.8%, and ROE of -19.2% in 2026Q2 shows equity is being consumed rather than compounded.

The consistency of negative ROIC over ten quarters suggests the business has not yet converted its invested capital into a return above its cost, and no period shows a sustained reversal. ROE swings between -2.3% and -51.8% reflect both losses and a shrinking equity base, which can distort the signal and should be read alongside asset trends. Investors should monitor whether the company can move ROIC toward breakeven, since the current record suggests value destruction rather than compounding.

Current Ratio Adequate on Paper, Cash Thin

A current ratio of 2.32 and quick ratio of 2.09 in 2026Q2 appear adequate, but cash fell to roughly $4.3M from $59.1M in 2025Q3, which narrows the real buffer against ongoing burn.

The ratio profile looks comfortable in isolation, yet the sharp decline in cash suggests current assets may be concentrated in items that are less liquid than headline cash implies, a point that warrants further investigation against the full balance sheet. The gap between a 2.32 current ratio and the thin cash position indicates the company's liquidity depends on the composition of working assets rather than cash alone. Under continued operating burn, the cushion could tighten quickly, so investors should monitor the cash runway against quarterly cash consumption.

Low Debt Ratio Masks Equity Dependence

A debt-to-equity ratio of 0.27 looks modest, but reported retained earnings deficits and negative free cash flow in every quarter suggest the company relies on external equity capital rather than debt-financed growth.

The low leverage reading may be misapplied as a signal of balance sheet strength, when in this case it primarily reflects limited borrowing rather than self-funded operations. Because operating cash flow has been negative throughout the window, the company's funding depends on sources outside operations, and the debt ratio alone does not capture that dependence. Interest coverage is largely unavailable or negative, so debt service capacity cannot be assessed from the supplied data, and investors should avoid drawing comfort from the leverage ratio without considering the funding trajectory.

Download Financial Ratios Data

Includes 30+ ratios · 14 years · Updated daily

Consensus & Technical Research Suite
Open MDWD Terminal

MDWD Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

MDWD — Frequently Asked Questions

Quick answers to the most common questions about buying MDWD stock.

What is MediWound Ltd.'s P/E ratio?

MediWound Ltd.'s current P/E ratio is -9.1x. The historical average is 17.2x.

What is MediWound Ltd.'s ROE?

MediWound Ltd.'s return on equity (ROE) is -63.9%. The historical average is -70.9%.

Is MDWD stock overvalued?

Based on historical data, MediWound Ltd. is trading at a P/E of -9.1x. Compare with industry peers and growth rates for a complete picture.

What are MediWound Ltd.'s profit margins?

MediWound Ltd. has 19.2% gross margin and -149.1% operating margin.